5 big analyst AI moves: Apple lifted to Buy, AI chip bets reassessed
Investing.com -- Genprex (NASDAQ:GNPX) stock surged 25% after the company announced that its research collaborators will present positive preclinical data on its Reqorsa® Gene Therapy for treating lung cancer at the upcoming 2025 AACR-NCI-EROTC International Conference.
The data shows that Reqorsa (quaratusugene ozeplasmid) demonstrated effectiveness against ALK-EML4 positive non-small cell lung cancer (NSCLC), with tumor shrinkage of 79% when used alone or in combination with alectinib. This represents a 23% improvement compared to alectinib alone, which showed 60% tumor shrinkage.
The preclinical research, conducted at the University of Michigan Rogel Cancer Center, suggests Reqorsa may be effective both as a standalone treatment and as a companion therapy for patients with advanced disease or those who cannot tolerate alectinib.
"We are delighted to have our academic partners present this compelling preclinical evidence that supports the therapeutic use of REQORSA in ALK Positive NSCLC," said Ryan Confer, President and Chief Executive Officer at Genprex . "Our researchers found that REQORSA alone or in combination with alectinib was able to shrink tumors by 79 percent, suggesting that REQORSA may be active as a single agent and may also be an ideal companion drug for patients with advanced disease."
The research indicates that Reqorsa works by upregulating the tumor suppressor gene TUSC2, which has low expression in NSCLC. The therapy delivers the functional TUSC2 gene to cancer cells using non-viral lipid nanoparticles.
According to the company, ALK+ lung cancers inevitably develop resistance to ALK inhibitors, creating a need for new treatment approaches. The findings will be presented at the conference taking place October 22-26 in Boston.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.